The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2019

Changes over time for: Section 3

Alternative versions:

31/12/2020- Amendment

Changes to legislation:

There are currently no known outstanding effects for the The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2019, Section 3.

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Amendment of the Quality and Safety of Organs Intended for Transplantation Regulations 2012U.K.

This section has no associated Explanatory Memorandum

3.—(1) The Quality and Safety of Organs Intended for Transplantation Regulations 2012 M1 are amended as follows.

(2) In regulation 3 (interpretation)—

(a)the existing text becomes paragraph (1);

(b)in that paragraph (1)—

[F1(i)n the definition of “the Directive”, at the end insert “, as it applies in relation to Northern Ireland”;]

[F2(ii)in the definition of “the Implementing Directive”, at the end insert “, as it applies in relation to Northern Ireland”;]

(iii)after the definition of “procurement activity” insert—

““procurement organisation” means a healthcare establishment, a team or a unit of a hospital, a person, or any other body which undertakes or coordinates the procurement of organs, and is authorised to do so by the Authority;”;

(c)after paragraph (1) insert—

“(2) In these Regulations, [F3as they apply in relation to Great Britain,] a reference to ensuring compliance with these Regulations includes a reference to ensuring compatibility with the principles set out in Article 13 of Directive 2010/53/EU of the European Parliament and of the Council on standards of quality and safety of human organs intended for transplantation as modified by section 32(3C) of the 2004 Act.”.

[F4(3) For regulation 4 (designation of the competent authority) substitute—

“Designation of the competent authority in relation to Northern Ireland

4. In relation to Northern Ireland, the Authority is designated the competent authority for the purposes of the Directive.”.]

(4) In regulation 5 (licensing requirement), at the end insert—

“(6) Schedule 1A (which specifies information to be collected in certain circumstances for the purposes of paragraph 5 of Schedule 1) has effect.”.

(5) In regulation 6 M2 (application of the 2004 Act in relation to licences under Schedule 1), for “the Directive and the Implementing Directive”, in each place where those words appear, substitute “[F5these Regulations, as they apply in relation to Great Britain, and with the Directive and the Implementing Directive, as they apply in relation to Northern Ireland]”.

(6) In regulation 12 M3 (guidance), in paragraph (1) for “the Directive and the Implementing Directive” substitute “ [F6these Regulations, as they apply in relation to Great Britain, and with the Directive and the Implementing Directive, as they apply in relation to Northern Ireland]”.

(7) In regulation 13 M4 (framework and compliance with licensing conditions and directions), in paragraph (1) omit “in compliance with the Directive and the Implementing Directive”.

[F7(8) For regulation 18 (organs sent to or received from another country), substitute—

“18.—(1) Where an organ is sent to a Member State from Northern Ireland, the Authority shall ensure that—

(a)information on organ and donor characterisation that is specified in Part A of the Annex to the Directive;

(b)information that has been collected by a registered medical practitioner or a person acting under their supervision that is required by Part B of the Annex at the time when the organ is sent to a Member State; and

(c)information to ensure the traceability of the organ,

is transmitted to that Member State in conformity with the requirements of Articles 4, 5, and 6(1) of the Implementing Directive.

(2) Where an organ is received in Northern Ireland from a Member State, the Authority shall ensure that—

(a)the requirements of Article 4 of the Implementing Directive in relation to information transmitted to the Authority in accordance with that Directive in respect of the organ have been complied with; and

(b)information to ensure the traceability of the organ is transmitted in accordance with Article 6(2) of that Directive.

(3) Where an organ is sent from Northern Ireland to, or received in Northern Ireland from, a Member State, the Authority shall ensure the reporting of serious adverse events and reactions in conformity with the requirements of Articles 4 and 7 of the Implementing Directive.

(4) The Authority shall ensure that any organs sent from Northern Ireland to, or received in Northern Ireland from, countries which are not in the European Union—

(a)can be traced from the donor to the recipient; and

(b)meet quality and safety standards that are equivalent to those required by these Regulations.

(5) The Authority shall ensure that any organs sent from Great Britain to, or received in Great Britain from, countries outside the United Kingdom—

(a)can be traced from the donor to the recipient; and

(b)meet quality and safety standards that are equivalent to those required by these Regulations.

(6) For the purposes of paragraphs (4) and (5), the Authority may conclude agreements with countries outside the United Kingdom.”.]

[F8(9) In regulation 19 (European Union network of competent authorities), after “The Authority shall,” insert “in relation to Northern Ireland,]

(10) In regulation 24 (review) omit subsection (2).

(11) After regulation 24 insert—

“PART 5AU.K.Power to amend data sets specified in Schedule 1A [F9in relation to Great Britain]

Power for appropriate authority to amend Schedule 1A [F10in relation to Great Britain]

24A.—(1) [F11An appropriate authority in Great Britain may by regulations amend—]

(a)the minimum data set specified in Part A of Schedule 1A (organ and donor characterisation) where the appropriate authority considers, on the basis of scientific evidence, that the amendment is justified by a serious risk to human health;

(b)the complementary data set specified in Part B of that Schedule where the appropriate authority considers, on the basis of scientific evidence, that it is appropriate to do so.

(2) In this regulation—

“appropriate authority” means—

(a)

in relation to England, the Secretary of State;

(b)

in relation to Wales—

(i)

the Welsh Ministers; or

(ii)

the Secretary of State acting with the consent of the Welsh Ministers;

(c)

in relation to Scotland—

(i)

the Scottish Ministers; or

(ii)

the Secretary of State acting with the consent of the Scottish Ministers;

(d)

F12...

(e)

[F13for the whole of Great Britain, the Secretary of State acting with the consent of the Welsh Ministers and the Scottish Ministers.]

Scope and nature of powers

24B.—(1) Regulations made by the Secretary of State or the Welsh Ministers under regulation 24A are to be made by statutory instrument.

(2) For regulations made under regulation 24A by the Scottish Ministers see section 27 of the Interpretation and Legislative Reform (Scotland) Act 2010 M5 (Scottish statutory instruments).

F14(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(4) Any power in regulation 24A to make regulations includes power to make—

(a)different provision for different purposes;

(b)consequential, supplementary, incidental, transitional, transitory or saving provision.

Scrutiny of regulations

24C.—(1) A statutory instrument containing regulations made by the Secretary of State under regulation 24A is subject to annulment in pursuance of a resolution of either House of Parliament.

(2) Regulations made under regulation 24A by the Scottish Ministers are subject to the negative procedure (see section 28 of the Interpretation and Legislative Reform (Scotland) Act 2010 (instruments subject to the negative procedure)).

(3) A statutory instrument containing regulations made by the Welsh Ministers under regulation 24A is subject to annulment in pursuance of a resolution of the National Assembly for Wales.

F15(4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”.

(12) In Schedule 1 (licences)—

(a)in paragraph 3(a) omit “European Union,”;

(b)in paragraph 5(b)—

(i)in paragraph (i), for “the Annex to the Directive” substitute “ Schedule 1A ”;

(ii)in paragraph (ii), for the words from “the Annex” to the end substitute “ Schedule 1A ”;

(c)in paragraph 7 for “the Annex to the Directive” substitute “ Schedule 1A ”.

(13) After Schedule 1 insert—

Regulation 5

“SCHEDULE 1AU.K.Organ and Donor Characterisation

PART AU.K.Minimum data set

1. The information to be collected pursuant to paragraph 5(b)(i) of Schedule 1 for organ and donor characterisation is the following (the “minimum data set”)—

(a)the establishment where the procurement takes place and other general data;

(b)type of donor;

(c)blood group;

(d)gender;

(e)cause of death;

(f)date of death;

(g)date of birth or estimated age;

(h)weight;

(i)height;

(j)past or present history of IV drug abuse;

(k)past or present history of malignant neoplasia;

(l)present history of other transmissible disease;

(m)HIV, HCV, HBV tests;

(n)basic information to evaluate the function of the donated organ.

PART BU.K.Complementary data set

2. The information to be collected pursuant to paragraph 5(b)(ii) of Schedule 1 for organ and donor characterisation is the following (the “complementary data set”)—

General data

(a)Contact details of the procurement organisation and (if different) the establishment where the procurement takes place necessary for coordination, allocation and traceability of the organs from donors to recipients and vice versa.

Donor data

(b)Demographic and anthropometrical data required in order to guarantee an appropriate matching between the donor or organ and the recipient.

Donor medical history

(c)Medical history of the donor, in particular the conditions which might affect the suitability of the organs for transplantation and imply the risk of disease transmission.

Physical and clinical data

(d)Data from clinical examination which are necessary for the evaluation of the physiological maintenance of the potential donor as well as any finding revealing conditions which remained undetected during the examination of the donor's medical history and which might affect the suitability of the organs for transplantation or might imply the risk of disease transmission.

Laboratory parameters

(e)Data needed for the assessment of the functional characterisation of the organs and for the detection of potentially transmissible diseases and of possible contraindications with respect to organ donation.

Image tests

(f)Image explorations necessary for the assessment of the anatomical status of the organs for transplantation.

Therapy

(g)Treatments administered to the donor and relevant for the assessment of the functional status of the organs and the suitability for organ donation, in particular the use of antibiotics, inotropic support or transfusion therapy.”.

(14) In Schedule 2 (directions of the Authority)—

(a)in paragraph 1, in sub-paragraph (e) omit “European Union,”;

[F16(b)for paragraph 3 substitute—

“3. For the purpose of ensuring compliance with the requirements of Articles 4(1), 4(2), 4(3), 5(2) and 5(3) of the Implementing Directive in relation to Northern Ireland, the Authority shall specify in directions given under section 23(1) of the 2004 Act the requirements relating to the transmission of information that apply to a licence holder when an organ is sent to, or received from, a Member State.”.]

Textual Amendments

F1Reg. 3(2)(b)(i) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 4(a)

F2Reg. 3(2)(b)(ii) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 4(b)

F3Words in reg. 3(2)(c) inserted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 4(c)

F4Reg. 3(3) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 5

F5Words in reg. 3(5) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 6

F6Words in reg. 3(6) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 7

F7Reg. 3(8) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 8

F8Reg. 3(9) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 9

F9Words in reg. 3(11) inserted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 10(a)

F10Words in reg. 3(11) inserted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 10(b)

F11Words in reg. 3(11) substituted (31.12.2020 immediately before IP completion day) by The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1305), regs. 1, 10(c)